New combo therapy targets liver metastases in hard-to-treat cancers
NCT ID NCT04701476
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests a two-part treatment for people with colorectal or non-small cell lung cancer that has spread to the liver and hasn't responded to standard therapies. The treatment combines a liver-directed procedure (TATE) that delivers a chemotherapy-like drug directly to the tumor with pembrolizumab, an immunotherapy that helps the immune system fight cancer. The goal is to see if this combination can shrink tumors and help people live longer.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for COLORECTAL CANCER; LUNG CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
China Medical University Hsinchu Hospital
RECRUITINGHsinchu, Taiwan
-
Chung Shan Medical University Hospital
RECRUITINGTaichung, Taiwan
-
University of California, Irvine Medical Center
RECRUITINGOrange, California, 92868, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a new immunotherapy combo outsmart advanced lung cancer?
- Double attack on mutant KRAS: can two targeted drugs outsmart resistant cancers?
- Seeing the fight: new imaging tracer may reveal how immune cells attack lung cancer
- Could a bronchial wash detect lung cancer mutations faster?
- Can delivering cancer drug directly to the liver shrink tumors?
- Can a targeted pill outsmart a tough lung cancer mutation?